Key result
Modified shock index ≥0.93 at presentation predicts ~100% higher six-month mortality in STEMI patients.
Why the study?
Prompt identification of higher-risk STEMI patients at presentation is crucial to guide more aggressive treatment approaches, but effective bedside risk assessment tools are needed.
Does a modified shock index (MSI) ≥ 0.93 predict six-month mortality in patients presenting with STEMI without cardiogenic shock?
Population
1158 STEMI patients without cardiogenic shock on admission
Comparison
Modified shock index (MSI) ≥ 0.93 vs MSI < 0.93
Design
Single-center retrospective observational cohort study
Follow-up
Six months
Authors
Loading...
May aid bedside risk stratification in STEMI; hypothesis-generating pending prospective validation.
Cohort (n=1,158)
No
Does a modified shock index (MSI) ≥ 0.93 predict six-month mortality in patients presenting with STEMI without cardiogenic shock?
Hazard Ratio: 2 (95% CI 1.2–3.34)
p-value: p=0.008
A modified shock index ≥ 0.93 at presentation is a simple bedside tool that independently predicts six-month mortality in STEMI patients without cardiogenic shock.
Abreu et al. (2018) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=1,158). Modified shock index (MSI) ≥0.93 vs. MSI <0.93 was evaluated on six-month all-cause mortality (HR 2.00, 95% CI 1.20-3.34, p=0.008). A modified shock index ≥0.93 at presentation was an independent predictor of six-month all-cause mortality in STEMI patients (adjusted HR 2.00; 95% CI 1.20-3.34; p=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: